A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Coronary Syndrome, Chronic Coronary Syndrome. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Study on Integrated Multi-Omics and Multi-Factor Analysis of Peripheral Blood in Patients With Acute Coronary Syndrome
Overview
The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are: The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.
Primary outcome measures
- circulating fibroblast growth factors (FGFs) levels [Time frame: within 24 hours of admission to the hospital]
- circulating inflammatory cytokines levels [Time frame: within 24 hours of admission to the hospital]
- circulating chemokines levels [Time frame: within 24 hours of admission to the hospital]
- circulating Cytochrome C level [Time frame: within 24 hours of admission to the hospita]
- circulating mitochondrial DNA levels [Time frame: within 24 hours of admission to the hospital]
- circulating malondialdehyde levels [Time frame: within 24 hours of admission to the hospital]
Secondary outcome measures (7)
- the relationship between FGFs/inflammatory cytokines/chemokines and troponin I (TnI) [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and brain natriuretic peptide (BNP) [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and lactate dehydrogenase (LDH) [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and left ventricular ejection fraction (LVEF) [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and mitochondrial DNA (mitoDNA) [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and cytochrome c [Time frame: within 24 hours of admission to the hospital]
- the relationship between FGFs/inflammatory cytokines/chemokines and malondialdehyde [Time frame: within 24 hours of admission to the hospital]
Eligibility criteria
Inclusion criteria
For ACS group STEMI
- cTn>99th ULN or CK-MB>99th ULN
- ST-segment elevation with a convex upward morphology
- in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
NSTEMI
- cTn>99th ULN or CK-MB>99th ULN
- accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.
UA
- cTn normal
- ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves
- evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group
- Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD
- Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group
- Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy
Exclusion criteria
- Lactating or pregnant women
- Patients with malignant neoplasms
- Severe hepatic/renal dysfunction
- Severe hematological disorders
- Autoimmune diseases
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- Lishui Central Hospital — Lishui
Identifiers
NCT: NCT06955143 · SAHoWMU-CR2025-06-218